Literature DB >> 3523486

Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.

A G Geiser, C J Der, C J Marshall, E J Stanbridge.   

Abstract

A human tumor cell line (EJ) expressing an activated c-Ha-ras oncogene was fused with a normal human fibroblast cell line. This fusion resulted in hybrids that behaved as transformed cells in culture but failed to form tumors in nude (athymic) mice. After repeated cell passage, two tumorigenic segregants of the hybrids arose in culture. The levels of expression of activated c-Ha-ras mRNA and its protein product, p21, were similar in the EJ cell line, the nontumorigenic hybrids, and the tumorigenic segregants. DNA transfections of the hybrids were performed with activated c-Ha-ras plasmid constructs, and transfectants expressing a 2-fold level of c-Ha-ras relative to the hybrid cells were found to maintain the nontumorigenic phenotype. We suggest that expression of the active c-Ha-ras oncogene is insufficient for the malignant transformation of these human cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523486      PMCID: PMC323920          DOI: 10.1073/pnas.83.14.5209

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in DNA of uninfected vertebrates.

Authors:  D H Spector; H E Varmus; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

2.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

3.  Differential effects of transforming avian RNA tumor viruses on avian macrophages.

Authors:  E M Durban; D Boettiger
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

4.  Suppression of tumorigenicity in somatic cell hybrids. I. Suppression and reexpression of tumorigenicity in diploid human X D98AH2 hybrids and independent segregation of tumorigenicity from other cell phenotypes.

Authors:  H P Klinger
Journal:  Cytogenet Cell Genet       Date:  1980

5.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

Authors:  C J Marshall; L M Franks; A W Carbonell
Journal:  J Natl Cancer Inst       Date:  1977-06       Impact factor: 13.506

7.  Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol.

Authors:  R L Davidson; P S Gerald
Journal:  Somatic Cell Genet       Date:  1976-03

8.  Target cell specificity of defective avian leukemia viruses: hematopoietic target cells for a given virus type can be infected but not transformed by strains of a different type.

Authors:  T Graf; H Beug; M J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

9.  Transforming activity of human tumor DNAs.

Authors:  T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

10.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

View more
  22 in total

1.  Exaggerated triglyceride accretion in human preadipocyte-murine renal line hybrids composed of cells from massively obese subjects.

Authors:  P E Le Blanc; D A Roncari; D I Hoar; A M Adachi
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Interferon-induced revertants of ras-transformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine.

Authors:  D Samid; D M Flessate; R M Friedman
Journal:  Mol Cell Biol       Date:  1987-06       Impact factor: 4.272

3.  Inhibition of voltage-dependent Na+ current in cell-fusion hybrids containing activated c-Ha-ras.

Authors:  M Estacion
Journal:  J Membr Biol       Date:  1990-02       Impact factor: 1.843

Review 4.  Suppression of the neoplastic phenotype and "anti-oncogenes".

Authors:  R Schäfer
Journal:  Blut       Date:  1987-05

5.  Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts.

Authors:  L J Joseph; L C Chang; D Stamenkovich; V P Sukhatme
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

6.  Role of a tumor-suppressor gene in the negative control of anchorage-independent growth of Syrian hamster cells.

Authors:  M Koi; C A Afshari; L A Annab; J C Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Extinction and activation of the thyroglobulin promoter in hybrids of differentiated and transformed thyroid cells.

Authors:  I M Bonapace; M Sanchez; S Obici; A Gallo; S Garofalo; R Gentile; S Cocozza; E V Avvedimento
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

8.  Tumor suppression involves down-regulation of interleukin 3 expression in hybrids between autocrine mastocytoma and interleukin 3-dependent parental mast cells.

Authors:  I D Diamantis; A P Nair; H H Hirsch; C Moroni
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  High-level expression of c-H-ras1 fails to fully transform rat-1 cells.

Authors:  M H Ricketts; A D Levinson
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

10.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.

Authors:  A G Geiser; S J Kim; A B Roberts; M B Sporn
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.